Tags

Type your tag names separated by a space and hit enter

Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
Vascul Pharmacol. 2008 Apr-Jun; 48(4-6):191-201.VP

Abstract

Tumour angiogenesis is a complex mechanism consisting of multi-step events including secretion or activation of angiogenic factors by tumour cells, activation of proteolytic enzymes, proliferation, migration and differentiation of endothelial cells. Both primary and metastatic tumours in the breast are dependent on angiogenesis. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN), one dosage per day along with tamoxifen (TAM) 10 mg twice a day. Serum pro-angiogenic levels were elevated in untreated breast cancer patients (Group II) and their levels were found to be reduced in breast cancer patients undergoing TAM therapy for more than 1 year (Group III). When these group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with TAM, a further significant reduction in pro-angiogenic marker levels were observed. Supplementing CoRN to breast cancer patients has found to decrease the levels of pro-angiogenic factors and increase the levels of anti-angiogenic factors. A reduction in pro-angiogenic marker levels attributes to reduction in tumour burden and may suggest good prognosis and efficacy of the treatment, and might even offer protection from cancer metastases and recurrence.

Authors+Show Affiliations

Department of Medical Biochemistry, DR. A.L.M. Post-Graduate, Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18407793

Citation

Premkumar, Vummidi Giridhar, et al. "Anti-angiogenic Potential of CoenzymeQ10, Riboflavin and Niacin in Breast Cancer Patients Undergoing Tamoxifen Therapy." Vascular Pharmacology, vol. 48, no. 4-6, 2008, pp. 191-201.
Premkumar VG, Yuvaraj S, Sathish S, et al. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol. 2008;48(4-6):191-201.
Premkumar, V. G., Yuvaraj, S., Sathish, S., Shanthi, P., & Sachdanandam, P. (2008). Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascular Pharmacology, 48(4-6), 191-201. https://doi.org/10.1016/j.vph.2008.02.003
Premkumar VG, et al. Anti-angiogenic Potential of CoenzymeQ10, Riboflavin and Niacin in Breast Cancer Patients Undergoing Tamoxifen Therapy. Vascul Pharmacol. 2008 Apr-Jun;48(4-6):191-201. PubMed PMID: 18407793.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. AU - Premkumar,Vummidi Giridhar, AU - Yuvaraj,Srinivasan, AU - Sathish,Sivaprakasam, AU - Shanthi,Palanivel, AU - Sachdanandam,Panchanatham, Y1 - 2008/03/05/ PY - 2007/10/21/received PY - 2008/02/19/accepted PY - 2008/4/15/pubmed PY - 2008/10/28/medline PY - 2008/4/15/entrez SP - 191 EP - 201 JF - Vascular pharmacology JO - Vascul. Pharmacol. VL - 48 IS - 4-6 N2 - Tumour angiogenesis is a complex mechanism consisting of multi-step events including secretion or activation of angiogenic factors by tumour cells, activation of proteolytic enzymes, proliferation, migration and differentiation of endothelial cells. Both primary and metastatic tumours in the breast are dependent on angiogenesis. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN), one dosage per day along with tamoxifen (TAM) 10 mg twice a day. Serum pro-angiogenic levels were elevated in untreated breast cancer patients (Group II) and their levels were found to be reduced in breast cancer patients undergoing TAM therapy for more than 1 year (Group III). When these group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with TAM, a further significant reduction in pro-angiogenic marker levels were observed. Supplementing CoRN to breast cancer patients has found to decrease the levels of pro-angiogenic factors and increase the levels of anti-angiogenic factors. A reduction in pro-angiogenic marker levels attributes to reduction in tumour burden and may suggest good prognosis and efficacy of the treatment, and might even offer protection from cancer metastases and recurrence. SN - 1537-1891 UR - https://www.unboundmedicine.com/medline/citation/18407793/Anti_angiogenic_potential_of_CoenzymeQ10_riboflavin_and_niacin_in_breast_cancer_patients_undergoing_tamoxifen_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1537-1891(08)00027-X DB - PRIME DP - Unbound Medicine ER -